logo
Plus   Neg
Share
Email

Northrop Grumman Gets US Approval To Buy Orbital ATK; Lifts 2018 Outlook

Northrop Grumman Corp.(NOC) said Tuesday that the U.S. Federal Trade Commission or FTC has cleared Northrop Grumman's proposed acquisition of Orbital ATK Inc. The FTC's Bureau of Competition has completed its review of the merger, and the Premerger Notification Office has informed the company that the waiting period under the HSR Act has terminated, allowing the companies to complete the merger.

As part of that clearance, the FTC issued a decision and order providing for solid rocket motors to be available on a non-discriminatory basis under specified circumstances and under processes defined in the order. The company expects to complete the transaction after market close tomorrow and is issuing the following updated guidance. This updated guidance assumes the completion of the transaction tomorrow.

Northrop Grumman now expects 2018 sales of about $30 billion, earnings per share of $16.20 to $16.45. Previously, the company expected sales of about $27.00 billion, and earnings per share of $15.40 to $15.65. Wall Street currently is looking for fiscal year 2018 earnings of $15.85 per share on annual revenues of $27.12 billion.

Northrop Grumman stated that the updated 2018 guidance reaffirmed its stand-alone guidance provided on April 25, 2018 and reflected the expected results of Innovation Systems for the remainder of the year. Updated guidance reflects a partial year of acquisition-related purchased intangibles amortization of approximately $175 million; this estimate is subject to the completion of purchase accounting and other post-closing activities.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Zoom Video Communications (ZM) gained 4% on extended session Tuesday after the video conferencing software company reported a first-quarter results that trumped Wall Street estimates and issued a outlook for the second and full year 2021 that is expected to beat current expectations. First-quarter... The National Retail Federation Chief Economist Jack Kleinhenz said it was too early to say how quickly or smoothly the U.S. economy would stage a recovery following the "sizable disruptions" due to the coronavirus pandemic. However, he noted that the reopening of businesses and the resumption of economic activity is a significant step forward. Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products.
RELATED NEWS
Follow RTT